MediXall Group, Inc.
MDXL · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.92 | 1.56 | -0.33 |
| FCF Yield | -2,417.19% | -4.77% | -4.29% | -4.31% |
| EV / EBITDA | -1.00 | -11.88 | -17.91 | -13.99 |
| Quality | ||||
| ROIC | 145.40% | 770.88% | -14,591.13% | -997.28% |
| Gross Margin | 23.56% | -5,296.21% | -20,349.52% | 0.00% |
| Cash Conversion Ratio | 0.27 | 0.52 | 0.76 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 174.28% | – | 77.42% | -100.00% |
| Free Cash Flow Growth | 65.49% | 24.17% | -30.69% | -52.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.98 | -0.43 | -0.04 | 0.07 |
| Interest Coverage | -6.05 | -24.12 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,357.34 | -125.56 | -70.09 | -82.43 |